BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 18418212)

  • 1. Capecitabine: an overview of the side effects and their management.
    Saif MW; Katirtzoglou NA; Syrigos KN
    Anticancer Drugs; 2008 Jun; 19(5):447-64. PubMed ID: 18418212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
    J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of capecitabine dosing in colorectal cancer.
    Sun W
    Clin Colorectal Cancer; 2010 Jan; 9(1):31-9. PubMed ID: 20100686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
    Aprile G; Mazzer M; Moroso S; Puglisi F
    Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects.
    Stathopoulos GP; Koutantos J; Lazaki H; Rigatos SK; Stathopoulos J; Deliconstantinos G
    Anticancer Res; 2007; 27(3B):1653-6. PubMed ID: 17595791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.
    Iqbal S; Lenz HJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):947-55. PubMed ID: 15606325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine in the treatment of colorectal cancer.
    O'Neill VJ; Cassidy J
    Future Oncol; 2005 Apr; 1(2):183-90. PubMed ID: 16555988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
    Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rational development of capecitabine from the laboratory to the clinic.
    Pentheroudakis G; Twelves C
    Anticancer Res; 2002; 22(6B):3589-96. PubMed ID: 12552961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine in breast cancer: current status.
    Smorenburg CH; Bontenbal M; Verweij J
    Clin Breast Cancer; 2001 Jan; 1(4):288-93; discussion 294. PubMed ID: 11899351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine].
    Saeki T; Takashima S
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):447-55. PubMed ID: 10097741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours.
    Sternberg CN; Reichardt P; Holland M
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S4-15. PubMed ID: 15341878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Xeloda in colorectal cancer.
    Cassidy J
    Int J Clin Pract; 2001 Jun; 55(5):326-8. PubMed ID: 11452682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential regional differences for the tolerability profiles of fluoropyrimidines.
    Haller DG; Cassidy J; Clarke SJ; Cunningham D; Van Cutsem E; Hoff PM; Rothenberg ML; Saltz LB; Schmoll HJ; Allegra C; Bertino JR; Douillard JY; Gustavsson BG; Milano G; O'Connell M; Rustum Y; Tabernero J; Gilberg F; Sirzén F; Twelves C
    J Clin Oncol; 2008 May; 26(13):2118-23. PubMed ID: 18445840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical considerations in the use of oral fluoropyrimidines.
    Hoff PM
    Semin Oncol; 2003 Jun; 30(3 Suppl 6):88-92. PubMed ID: 12802799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
    Petrioli R; Pascucci A; Francini E; Marsili S; Fiaschi AI; Civitelli S; Tanzini G; Battistelli S; Lorenzi M; Roviello F; Francini G;
    Anticancer Drugs; 2008 Jan; 19(1):91-6. PubMed ID: 18043134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
    Cunningham D; Coleman R
    Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.
    Dennie TW; Fleming RA; Bowen CJ; Dar MM; Alberti D; Oliver K; Loconte N; Mulkerin D; Holen KD
    Clin Colorectal Cancer; 2011 Mar; 10(1):57-62. PubMed ID: 21609937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.